EU/3/04/205: Orphan designation for the treatment of cutaneous T-cell lymphoma

Suberolylanilide hydroxamic acid

Table of contents


Please note that this product was withdrawn from the Community register of designated orphan medicinal products in February 2013 on request of the sponsor.

On 21 June 2004, orphan designation (EU/3/04/205) was granted by the European Commission to Stringer Consultancy Services Ltd, United Kingdom, for suberoylanilide hydroxamic acid (SAHA) for the treatment of cutaneous T-cell lymphoma.

The sponsorship was transferred to Merck Sharp & Dohme Limited, United Kingdom, in September 2004.

Key facts

Active substance
Suberolylanilide hydroxamic acid
Intended use
Treatment of cutaneous T-cell lymphoma
Orphan designation status
EU designation number
Date of designation
Merck Sharp & Dohme Limited
Hertford Road
EN11 9BU
United Kingdom
Tel. +44 (0)1992 467272
Fax +44 (0)1992 479191

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating